Hepatitis Forums
Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on August 23, 2018, 10:28:33 am
-
Those who do not adhere well to the daily regimen of Baraclude (entecavir) for hepatitis B virus (HBV) have a higher risk of hepatocellular carcinoma (HCC, the most common form of liver cancer), cirrhosis-related complications and death, Healio reports.
Publishing their findings in the American Journal of Gastroenterology, researchers conducted a longitudinal observational study between January 2007 and January 2017 of 894 people with HBV who had not yet been treated for the virus before starting Baraclude. The median follow-up time was 5.4 years.
Read more...
https://www.hepmag.com/article/poor-adherence-hepatitis-b-treatment-raises-liverhealth-risks